

# Ibopamine eye drops in the treatment of hypotony after vitreoretinal surgery in retinal detachment or uveitis

<b>Submission date</b> 20/12/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 20/12/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 04/11/2008	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr J C van Meurs

**Contact details**  
Oogziekenhuis Rotterdam  
Schiedamsevest 180  
Rotterdam  
Netherlands  
3011 BH  
+31 (0)10 401 7777  
vanMeurs@oogziekenhuis.nl

## Additional identifiers

**Protocol serial number**  
OZR-2002-17; NTR187

## Study information

**Scientific Title**

**Study objectives**

Administration of Ibopamine hydrochloride eye drops restores intraocular pressure in patients with hypotony following vitreoretinal surgery or uveitis.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Received from the local medical ethics committee

**Study design**

Randomised, single blinded, placebo controlled, crossover trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Ocular hypotony following either vitreoretinal surgery or uveitis

**Interventions**

Treatment with ibopamine hydrochloride (0.5 % or 2%) eye drops or placebo.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Ibopamine hydrochloride

**Primary outcome(s)**

Ocular pressure on treatment day

**Key secondary outcome(s))**

No secondary outcome measures

**Completion date**

01/04/2003

**Eligibility****Key inclusion criteria**

1. Hypotony (0 - 5 mmHg)
2. Stable eye pressure for at least 4 months

3. No reaction of eye pressure to atropine and steroids
4. Continued steroid treatment during past six months
5. Status after vitreoretinal surgery or uveitis

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. Chronic heart failure
2. Traction on corpus ciliare
3. Cyclodialysis

**Date of first enrolment**

01/01/2003

**Date of final enrolment**

01/04/2003

**Locations****Countries of recruitment**

Netherlands

**Study participating centre**

Oogziekenhuis Rotterdam

Rotterdam

Netherlands

3011 BH

**Sponsor information****Organisation**

Rotterdam Eye Hospital (Oogziekenhuis Rotterdam) (The Netherlands)

**ROR**

<https://ror.org/02hjc7j46>

# Funder(s)

## Funder type

Hospital/treatment centre

## Funder Name

Foundation of Scientific Research at the Eye Hospital (Stichting Wetenschappelijk Onderzoek het Oogziekenhuis) (The Netherlands)

# Results and Publications

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	Results	01/03/2006		Yes	No